New products lead Nicholas' growth - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

New products lead Nicholas' growth

Oct 19, 2000

Nicholas Piramal has reported an above average topline growth of 17% (vis–a–vis the overall domestic pharmaceutical growth of 10.8%) primarily due to introduction of new products such as Rejoint as well as Omnatax and Haemaccel which were acquired from Hoechst Marrion last year. Of the 19% growth in formulation sales in the second quarter almost 9% was from the acquired brands. Vitamin A which contributed around 13% to the company's turnover showed a growth of 10%. Besides, the company has been a beneficiary of the price hike that would yield Rs 40 m in the current year.

(Rs m)2QFY002QFY01Change
Sales1229.101441.6017.3%
Other Income41.9019.50-53.5%
Expenditure1057.701209.5014.4%
Operating Profit (EBDIT)171.40232.1035.4%
Operating Profit Margin (%)13.95%16.10% 
Interest 28.703.80-86.8%
Depreciation24.9033.4034.1%
Profit before Tax159.70214.4034.3%
Other Adjustments   
Tax18.5029.8061.1%
Profit after Tax/(Loss)141.20184.6030.7%
Net profit margin (%)11.49%12.81% 
Earnings Per Share16.2121.19 
(annualised)   

The company's R & D is focussing on five New Chemical Entities of which two are in the cardiovascular segment, one addresses the anti–cancer segment, one addresses the anti–diabetic segment and one for the fungal segment. These are expected to take around one and a half years more before the company reaches the stage of clinical trials.

However, the company's plans to float a US $ 70m –100m ADR issue have been deferred. The resources were to be used for upgrading its research for Mulund and setting up a a clinical research facility. A part of the proceeds was to be used to fund acquisitions both domestic and overseas. The managment was of the view that the company would raise resources via borrowings and tighten working capital management.

The stock quotes a price of Rs 312, which implies an earnings multiple of 14.7 times FY01 earnings.

Equitymaster requests your view! Post a comment on "New products lead Nicholas' growth ". Click here!

  

More Views on News

PIRAMAL ENTERPRISES 2020-21 Annual Report Analysis (Annual Result Update)

Oct 26, 2021 | Updated on Oct 26, 2021

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY22); Net Profit Down 20.0% (Quarterly Result Update)

Aug 9, 2021 | Updated on Aug 9, 2021

For the quarter ended June 2021, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (down 20.0% YoY). Sales on the other hand came in at Rs 29 bn (down 1.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

Don't Sell these Stocks if the Market Falls (Profit Hunter)

Nov 17, 2021

These are the 3 types of stocks that you should not sell in a market crash.

How to Find Your Next 10-Bagger in this Market (Profit Hunter)

Nov 19, 2021

The #1 make or break factor in your portfolio you shouldn't ignore.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Nov 30, 2021 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 5-YR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS